4.7 Article

Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.ijantimicag.2022.106589

Keywords

Linezolid; Drug-resistant tuberculosis; Population pharmacokinetics; Pharmacodynamics; Dosage optimisation

Funding

  1. Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [ZYLX202123]

Ask authors/readers for more resources

This study aimed to find the optimal dosing regimen of linezolid in different populations. The results revealed that factors such as body weight and creatinine clearance significantly influenced the pharmacokinetics of linezolid. The study determined the optimal dosage regimens for patients with different body weights and MIC values, and found that single dosing was safer than multiple dosing.
Objectives: Linezolid can significantly impact drug-resistant tuberculosis (DR-TB) patient outcomes. How -ever, the long-term use of this drug for TB treatment has been limited by adverse reactions and uncertainty regarding optimal dosage regimens for balancing drug efficacy and safety across different populations. This study attempted to find the optimal dosing regimen of linezolid in different populations. Methods: A total of 355 blood samples were collected from 126 DR-TB patients. Population pharmacokinetic analysis (using a one-compartment model) and dose simulations were conducted using NONMEM and R software. The ratio between the area under the free drug plasma concentration-time curve to the MIC (fAUC/MIC) of > 119 and trough concentration (C-min) <= 2 mg/L served as efficacy and safety targets, respectively, toward the formulation of optimal dosage regimens based on a >= 90% cumulative fraction of response. Results: Body weight and blood urea nitrogen levels were the most significant covariates of apparent volume, while creatinine clearance and haemoglobin level significantly influenced apparent clearance. The probability of target attainment for different dosage regimens was evaluated via Monte Carlo simulation. For subjects with MICs of 0.125, 0.25 and 0.5 mg/L, specific total daily doses of > 300 mg, > 450 mg and > 900 mg were required to reach the target, respectively. Subjects with body weight < 70 kg and MIC > 1 mg/L received a total 1200 mg daily dose to reach the probability of target attainment target. Notably, single dosing was safer than multiple dosing at the same daily dose. The optimal dosage regimens for subjects with body weight < 50 kg and > 50 kg were 450 mg/d and 600 mg/d (once daily), respectively. Conclusion: Optimal dosage regimens for patients weighing < 50 kg and > 50 kg were 450 mg/d and 600 mg/d, respectively. A single dose was safer than multiple doses. (c) 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available